Shousha, 547 patient HCQ late treatment study: 12% lower mortality [p=0.87] https://c19p.org/shoushah
copied to clipboard
Hepatic and gastrointestinal disturbances in Egyptian patients infected with coronavirus disease 2019: A multicentre cohort study
et al., World Journal of Gastroenterology, doi:10.3748/wjg.v27.i40.6951
Retrospective 547 hospitalized COVID+ patients in Egypt, showing no significant differences with CQ/HCQ treatment in unadjusted analysis. Treatments were applied according to patient conditions, demographics, and comorbidities as per the the official guidelines, indicating strong confounding by indication.
|
risk of death, 11.5% lower, RR 0.88, p = 0.87, treatment 12 of 136 (8.8%), control 41 of 411 (10.0%), NNT 87, unadjusted.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in meta
analysis:
confounding by indication, unadjusted results and treatment used selectively per official protocol, unadjusted results with no group details.
Shousha et al., 10/28/2021, retrospective, Egypt, Africa, peer-reviewed, 18 authors, study period 15 April, 2020 - 29 July, 2020.
Late treatment
is less effective
is less effective
shousha
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.